drugset / Trial / NCT03796182
Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants
RandomizedCrossoverOpen-labelTreatment
Summary
This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants. The effect of PF-04965842 on N1-methylnicotinamide (NMN; an endogenous biomarker for MATE1/2K) PK and its correlation to the effect on metformin PK will also be assessed. Participants will be randomized to 1 of 2 treatment sequences as described below. A total of 12 healthy male and/or female participants will be enrolled in the study so that 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods.
Timeline
- Start
- 2019-01-10
- Primary completion
- 2019-02-13
- Completion
- 2019-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abrocitinib | Small molecule | 100 mg | Oral |
| Subject | Metformin | Small molecule | 500 mg | — |
Indications
No indication recorded.